GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

Pallavi Madhiraju- November 28, 2023

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More

Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma

Pallavi Madhiraju- May 28, 2023

Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More

Zydus Lifesciences gets FDA approval for Bortezomib for Injection

pallavi123- May 3, 2022

Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for ... Read More